
==== Front
Biomedicines
Biomedicines
biomedicines
Biomedicines
2227-9059
MDPI

34070746
10.3390/biomedicines9060619
biomedicines-09-00619
Review
Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification
Vallée Alexandre 1*
Lecarpentier Yves 2
Vallée Jean-Noël 34
Turcan Sevin Academic Editor
1 Department of Clinical Research and Innovation, Foch Hospital, 92150 Suresnes, France
2 Centre de Recherche Clinique, Grand Hôpital de l’Est Francilien (GHEF), 77100 Meaux, France; yves.c.lecarpentier@gmail.com
3 Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80000 Amiens, France; valleejn@gmail.com
4 Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, 86000 Poitiers, France
* Correspondence: alexandre.g.vallee@gmail.com
30 5 2021
6 2021
9 6 61904 5 2021
28 5 2021
© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Gliomas are the main common primary intraparenchymal brain tumor in the central nervous system (CNS), with approximately 7% of the death caused by cancers. In the WHO 2016 classification, molecular dysregulations are part of the definition of particular brain tumor entities for the first time. Nevertheless, the underlying molecular mechanisms remain unclear. Several studies have shown that 75% to 80% of secondary glioblastoma (GBM) showed IDH1 mutations, whereas only 5% of primary GBM have IDH1 mutations. IDH1 mutations lead to better overall survival in gliomas patients. IDH1 mutations are associated with lower stimulation of the HIF-1α a, aerobic glycolysis and angiogenesis. The stimulation of HIF-1α and the process of angiogenesis appears to be activated only when hypoxia occurs in IDH1-mutated gliomas. In contrast, the observed upregulation of the canonical WNT/β-catenin pathway in gliomas is associated with proliferation, invasion, aggressive-ness and angiogenesis.. Molecular pathways of the malignancy process are involved in early stages of WNT/β-catenin pathway-activated-gliomas, and this even under normoxic conditions. IDH1 mutations lead to decreased activity of the WNT/β-catenin pathway and its enzymatic targets. The opposed interplay between IDH1 mutations and the canonical WNT/β-catenin pathway in gliomas could participate in better understanding of the observed evolution of different tumors and could reinforce the glioma classification.

gliomas
glioblastomas
WNT/β-catenin pathway
IDH1
cancer
hypoxia
normoxia
==== Body
1. Introduction

Gliomas are the main common primary intraparenchymal brain tumor in the central nervous system (CNS), with approximately 7% of the death caused by cancers [1,2]. Gliomas are composed by a very heterogeneous group of primary CNS tumors, originally classified according to their microscopic similarity with presumed origin of non-neoplastic glial cells (including astrocytes—astrocytoma; oligodendroglial cells—oligodendroglioma; ‘glioblast’—glioblastoma). Gliomas are traditionally divided into two major categories: ‘diffuse’ gliomas and ‘non-diffuse’ tumors. Diffuse gliomas are characterized by tumor cell migration over large distances into the CNS parenchyma, with possible curative surgical resection. Malignancy grade was defined by the presence or the absence of marked mitotic activity, necrosis and/or florid micro- vascular proliferation. Non-diffuse gliomas are mainly much more circumscribed. Molecular mechanisms can help to categorize glial tumors into different diffuse and non-diffuse glioma entities. The tremendous increase in knowledge of the molecular characteristics of CNS tumors during the last decade has allowed for a paradigm shift. In the update of the 4th edition of the World Health Organization (WHO) classification CNS tumors published in 2016 [3,4], molecular dysregulations are part of the definition of particular brain tumor entities for the first time. Especially, the classification of the main frequent primary neoplasms of the CNS parenchyma itself, the diffuse gliomas, has undergone major restructuring based on the status of a few key molecular aberrations (Supplementary Materials). Nevertheless, the molecular mechanism that gliomas undergo remains unclear and needs to be clarified.

Mutations in enzymes regulating metabolite flux are implicated in gliomas development, as highlighted by the discovery of isocitrate dehydrogenase 1 (IDH1), in more than 70% of diffusely infiltrating WHO grade II and grade III astrocytic and oligodendroglial gliomas, as well as in a small fraction of glioblastomas (GBM), particularly those that develop from low-grade-gliomas (LGG) [3,5,6,7,8].

In parallel, a large number of studies have suggested that WNT signaling is aberrantly activated in GBM and that it promotes GBM growth and invasion [9,10,11,12,13].

However, very few studies have investigated the interplay between IDH1 mutations and WNT signaling in gliomas and thus, the repercussion in gliomas development.

IDH1 mutations have not been reported in pediatric gliomas, suggesting that IDH1 mutations are only restricted to astrocytomas and oligodendrogliomas in young adults [14,15,16]. Gliomas in children are predominantly driven by other mutations (with mutations at K27M or G34V or G34R). The nature of these different mutations, restricted to certain ages, suggest that pediatric and young adult gliomas may have different cells of origin [17]. Thus, this review is focused on the opposed interplay between IDH1 mutations and the canonical WNT/β-catenin in gliomas development in young adults.

2. IDH1 Mutations and Glioma

Glioblastomas (GBM) differ at the genetic and epigenetic levels, especially with the distinguishing feature in the identification of mutations in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1). IDH1 mutations are one of the earliest detectable genetic damages in low-grade gliomas [17]. IDH1 were reported in 2008 and the mutation of the arginine at codon 132 is the main frequent type. It was also reported that 80% to 90% of IDH1 mutations in astrocytic and oligodendroglial gliomas have the type R132H (arginine to histidine) [18,19,20]. Numerous studies showed that IDH1 mutations lead to better overall survival in gliomas patients and better response to therapies [21,22,23,24].

It was found that 75% to 80% of secondary GBM showed IDH1 mutations, whereas only 5% of primary GBM had IDH1 mutations [17,25]. Primary GBM were observed to have very low mutations levels in IDH1 (around <3%–5%)) [17,26]. IDH1 mutations had developed through progression from an anaplastic glioma (WHO Grade III), while the majority of secondary GBM with IDH1 mutations had progressed from a WHO Grade II glioma [19]. Moreover, to provide insights about the origin of gliomas, the mutational status of IDH1 serves as a prognostic factor in patients with WHO grade II and III gliomas [27] and GBM [28].

IDH1 is considered as a marker of secondary GBM and those primary GBMs diagnosed with IDH1 mutations may have been secondary gliomas that rapidly progressed to GBM with no early low-grade clinical symptoms experienced by patients [29]. IDH1 mutations occur early in glioma-genesis and occur in a progenitor cell that can give rise to both cell types. IDH1 mutations have not been reported in other CNS tumors including ependymomas, medulloblastomas, meningiomas, and pilocytic astrocytomas and are very rare in spinal gliomas [19,30,31,32]. In gliomas, the frequency of IDH1 mutations in codon 132 increases in the order R132L, R132S, R132G, R132C, to R132H, with R132H constituting more than 90% of all IDH1 mutations [21].

Somatic mutations in IDH1 genes have recently been identified in a large proportion of glial tumors of the CNS [4,21]. IDH1 mutation has been reported to be a strong and independent indicator for good prognosis in gliomas whatever the tumor grade [33].

IDH1 mutation was a positive prognostic marker, because patients with this mutation had significantly better overall survival [5]. Several studies also showed that patients with GBM or diffuse glioma with IDH1 mutations had better overall survival and progression-free survival [7,34,35,36,37,38,39].

Some studies showed that patients with IDH1 mutations versus those with wild-type IDH1 possessed significantly better overall survival times when treated with surgery and radiotherapy [40,41]. IDH1 mutations were associated with a better response to cytotoxic therapy and longer survival in malignant glioma patients [42,43]. In comparison with IDH-mutated LGG, primary GBM (IDH wild-type GBM) and IDH wild-type LGG were characterized by a clinically aggressive behavior with a dismal prognosis [27,44].

3. Non-IDH1-Mutated Glioma

Integrated genomic/transcriptome and epigenomic analysis resulted in a gene expression-based molecular classification of GBM into classical, mesenchymal (MES), proneural (PN), and neural subtypes, characterized by aberrations and gene expression of the epidermal growth factor receptor (EGFR), neurofibromatosis Type 1, and platelet-derived growth factor receptor a (PDGFRa). Previous studies showed that responses to aggressive chemotherapy and radiotherapy differed according to subtype [45].

The PN subgroup was enriched for mutations in IDH1, mutation in TP53, and amplifications of PDGFRa, cyclin-dependent kinase 6 (CDK6), CDK4, and receptor for hepatocyte growth factor (Met) [17]. Moreover, this group contained the highest percentage of young patients, likely because of the enrichment of IDH1 mutations, which is associated with younger patient age. The classical subtype is characterized by EGFR amplification and a loss of phosphatase and tensin homolog (PTEN). The classical subtype also harbors the mutant EGFR variant III (EGFRvIII) mutation, which is constitutively active and has an in-frame deletion of exons 2–7. The MES subclass is associated with poor overall survival, contains neurofibromatosis Type 1 mutations, and has a loss of TP53 and CDK inhibitor N2A (CDKN2A). Last, the neural subtype has elevated levels of neural markers such as NEFL but has no unique distinguishing alterations from other classes, although elevated rates of ERBB2 mutation were observed [17].

The genomic characterization of IDH wild-type GBM reveals frequent genetic alterations of key components of the growth factor receptor-PI3K-Akt signaling pathway that activates the mechanistic target of rapamycin (mTOR) signaling [46,47,48]. The EGFR is a major activator of a variety of pathways and physiological responses include proliferation, survival, migration, and tumorigenesis. EGFR is amplified in about 40% of GBM patients, and is often associated with high-grade classical tumors [25]. While it is commonly thought that amplification or mutation of EGFR is an indicator of poor survival, several studies failed to validate this conclusion [49]. Mutations and amplifications of EGFR and loss of chromosome 10 are rarely found in IDH1 mutant tumors [26].

The PI3K pathway is normally activated by the EGFR and other growth factor receptors [50]. EGFR binds PI3K/Akt/STAT and modulates proliferation, differentiation and survival [51,52]. PI3K is activated by EGFR. PI3K converts PIP2 in PIP3 [53,54]. The activity of PI3K is counteracted by PTEN, which converts PIP3 back to PIP2 [55]. PI3K activates Akt signaling by phosphorylation [56]. An increase in Akt signaling inhibits GSK-3β activity and leads to nuclear translocation and stability of β-catenin [53]. PI3K/Akt signaling regulates β-catenin stability, translocation, transcriptional activity and the expression of its downstream genes (such as Cyclin D1 and c-Myc) [54].

Approximately 40% of GBM have mutations in the PTEN protein and around 70% show a loss of heterozygosity at the PTEN locus [57]. The value of PTEN loss as a prognostic marker has not been validated, and is still somewhat controversial [58].

Recent studies identified a set of interlacing molecular mechanisms by which EGFRvIII, a constitutively activating mutant form of EGFR, co-opts c-Myc to reprogram cellular metabolism and drive tumor proliferation. This involves the mTOR complexes 1 and 2 (mTORC1 and mTORC2) [46,59]. Moreover, failure to inhibit mTOR signaling can render GBM cells resistant to PI3K/Akt-targeted therapies by maintaining elevated levels of c-Myc [59].

In EGFR-mutant GBM, which do not usually possess the mutations in IDH or H3 histone family 3A (H3F3A) to potentially change the epigenetics, constitutive PI3K activation could engage the epigenetic machinery through several complementary routes. First, EGFR activation causes the glycolytic enzyme pyruvate kinase isozymes M2 (PKM2) to translocate to the nucleus, where it phosphorylates histone 3 at Thr11, causing dissociation of histone deacetylase 3 (HDAC3), and promotes histone acetylation to regulate transcription of the cancer-promoting genes, including c-Myc and cyclin D1 [60].

In approximately 30% of human gliomas, expression of genes associated with PDGFR signaling and genes involved in oligodendrocyte development (OLIG2, NKX2-2, and PDGF), are observed and are thought to be hallmarks of the PN signature in GBM [9]. Amplification of the α-type PDGFR (PDGFRA) gene is found in 15% of all tumors, mainly in the PN subtype of GBM [45,61] and approximately 40% of tumors harboring gene amplification contain an intragenic deletion in this gene [62]. However, the expression of PDGFRB seems to be limited to proliferating endothelial cells in GBM [63,64]. Similar to EGFR and EGFRvIII, amplification of PDGF and PDGFR seems to promote aggressive glioma growth [65].

4. Canonical WNT/β-Catenin Pathway

The WNT name is derived from Wingless drosophila melanogaster and its mouse homolog Int. The WNT/β-catenin pathway is implicated in several mechanisms and controls signaling, including embryogenesis, cell proliferation, migration and polarity, apoptosis, and organogenesis [66]. Nevertheless, during several pathological diseases, the WNT/β-catenin pathway can be altered, to impact mechanisms including inflammation, metabolic, neurological and psychiatric disorders, fibrosis and cancer processes [67].

The WNT pathway belongs to the family of secreted lipid-modified glycoproteins [68]. WNT ligands are produced by neurons and immune cells localized in the CNS [69]. WNT pathway dysfunction could affect numerous neurodegenerative pathologies [70,71,72,73,74]. The WNT pathway has a main stage called the β-catenin/T-cell factor/lymphoid enhancer factor (TCF/LEF). Cytoplasmic accumulation of β-catenin is modulated by the destruction complex AXIN, tumor suppressor adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK-3β). With absence of WNT ligands, the destruction complex has a role in the hyper-phosphorylation of the cytoplasmic β-catenin and leads to its proteasomal destruction. Nevertheless, in their presence, the WNT ligands bind to Frizzled (FZL) and LDL receptor-related protein 5/6 (LRP 5/6) to interrupt the destruction complex and prevents β-catenin degradation into the proteasome. β-catenin translocates to the nucleus to interact with the TCF/LEF; this stimulates WNT target genes [75,76,77].

Glycogen synthase kinase-3β (GSK-3β) is one of the major inhibitors of the WNT/β-catenin pathway [78,79,80,81,82,83]. As an intracellular serine-threonine kinase, GSK-3β is a major negative controller of the WNT signaling [84]. GSK-3β is implicated in the control of numerous kinds of pathophysiological pathways, including cell membrane signaling, cell polarity, and inflammation [85,86,87]. GSK-3β interacts by downregulating the cytoplasmic β-catenin and stabilizing it to enhance its nuclear migration. Inflammation is an age-related mechanism correlated with the activation of GSK-3β pathway and the diminution of the WNT/β-catenin pathway [88].

Recent studies have observed that glaucoma patients presented activation of the GSK-3β pathway and its downregulation may be an interesting therapy target [89,90]. Dysregulation of GSK-3β is implicated in the pathogenesis of numerous pathologies, such as cancer processes [91,92,93]. GSK-3β is a regulator of numerous signaling including inflammation, neuronal polarity or cell membrane signaling [86]. GSK-3β is known to be the major inhibitor of the canonical WNT/β-catenin pathway [82,93,94,95,96,97].

5. Canonical WNT/β-Catenin Pathway in Glioma

A large number of studies have suggested that WNT signaling is aberrantly activated in GBM and that it promotes GBM growth and invasion via the maintenance of stem cell properties [9,10,11,12,13]. The nuclear accumulation of β-catenin is responsible for the malignant progression and β-catenin protein levels are correlated with malignancy and with the gene expression of cyclin D1 and c-Myc [98,99,100]. The aberrant activation of WNT/β-catenin pathway contributes to gliomas progression [98,99,101,102,103,104,105] (Figure 1).

Recent studies have described the functions of WNT/β-catenin pathway in development and cancer, with particular emphasis on genetic and epigenetic alterations that lead to aberrant WNT pathway activation in GBM [106,107,108,109,110]. Prominent genomic alterations frequently found in GBM include loss-of-function of tumor suppressors in the p53, phosphatase and tensin homolog and neurofibromatosis 1, and hyperactivation of receptor tyrosine kinase (RTK) signaling, including EGFR, PDGF receptor, and the receptor for hepatocyte growth factor (Met) [3].

Epigenetic silencing of negative effectors of WNT pathways can activate WNT signaling and contribute to malignant behavior in GBM. Soluble Frizzled-related proteins (FRPs) are soluble proteins that bind to WNT and interfere with WNT signaling. Dickkopf (DKK) acts as an antagonist of WNT signaling via binding to its co-receptor LRP [111]. Notably, epigenetic silencing of WNT pathway inhibitor genes frequently occurs in gliomas, including promoter hyper-methylation of sFRPs, Dickkopf-1 and Naked (NKD1, NKD2). In GBM, promoter hypermethylation of sFRP1, sFRP2 and NKD2 occurred in more than 40% of primary GBM specimens [112,113].

Epithelial–mesenchymal transition (EMT) is a critical process that enables cancer cells of epithelial origin to metastasize to distal organs. Unsurprisingly, WNT signaling is involved in both tumor invasion and EMT [12]. FZD4, a positive WNT regulator, was identified and shown to be a causative effector for invasive phenotypes of GBM cells [114].

Receptor tyrosine kinases (RTKs) promote GBM survival, proliferation, and invasion. Hyperactivation of RTK signaling because of genomic amplification and/or activating mutations of RTKs occurs in more than 90% of GBMs [45]. Amplifications or somatic mutations in EGFR, PDGF receptor, FGFR, and Met often correlate with GBM subtypes [45].

Activation of EGFR induces downstream mitogenic signaling, such as the mitogen-activated protein kinase, PI3K/Akt, and transducers and activators of transcription (STAT) pathways [115,116]. WNT pathway can induce activation of the Akt pathway [117].

Met has crucial roles in cancer growth, stem cell maintenance, and metastasis [118]. In GBM, expression levels of Met correspond with poor patient survival and malignancy [119]. In addition, analyses of clinical GBM specimens revealed a positive association between Met expression and invasiveness-related genes (matrix metalloproteinases: MMP2 and MMP9) and proto-oncogenes (c-Myc, KRAS, and JUN) [120,121]. Activation of Met signaling can be enabled by the addition of hepatocyte growth factor (HGF)-induced nuclear translocation of β-catenin [122].

6. Opposed Interplay between IDH1 Mutations and WNT/β-Catenin Pathway in Glioma

A recent study reported that the IDH1-R132H mutation causes both a less aggressive phenotype and radiosensitization of human malignant glioma cells [123]. Metastasis in cancer is initiated by a process called EMT transition that requires upregulation of β-catenin, the mediator of the canonical WNT pathway [124,125]. IDH1-R132H mutation leads to decreased activity of WNT/β-catenin pathway, that in turn curbs the elevated proliferation and migration observed in invasive gliomas [126]. The expression of mediators, effectors and targets of the canonical WNT pathway, including β-catenin, TCF4 and LEF1 is downregulated in glioma cells overexpressing IDH1-R132H [126]. In addition, negative regulators of WNT/β-catenin pathway, such as DKK1 and APC, are upregulated in these cells. The activity of the endpoint mediator of this pathway, TCF, is significantly downregulated in IDH1-R132H cells [126]. Thus, IDH1-R132H causes a significant reduction in the proliferation, migration and invasiveness of gliomas, accompanied by an increase in apoptotic cell death [127].

Glioma cells overexpressing IDH1-R132H displayed higher chemosensitivity due to increased generation of reactive oxygen species (ROS) and depletion of glutathione, suggesting that they respond better to chemotherapy than IDH1-wt gliomas [127,128].

The PI3K/Akt pathway is upregulated in invasive gliomas in association with the WNT/β-catenin pathway [92,129], and is known to induce tumor progression [130]. IDH1-R132H decreases the activity of the PI3K/Akt pathway in glioma cells [131]. Mutated IDH1 thus blocks PI3K/Akt signaling, a pathway associated with the development of a more aggressive glioma phenotype [132,133].

Recent studies have shown that the presence of IDH1-R132H mutation is associated with a better prognosis in glioma patients in association to the decrease in the expression of the WNT/β-catenin pathway [134]. Yao et al. demonstrated that IDH1 mutation diminished the malignant progression of glioma by causing a less aggressive phenotype of GSCs, which were involved in the WNT/β-catenin pathway [126,134]. Furthermore, IDH1 mutation is associated with the reduction in cell survival, proliferation and invasion of glioma by decreasing the WNT signaling [126,135] (Table 1).

7. Oxidative Stress and IDH1 Mutations in Glioma

Previous studies showed that elevated levels in tumor cells of reactive oxygen species (ROS) led to cell cycle arrest, inhibition of proliferation and promotion of apoptosis, thereby decreasing tumor growth [140,141]. An imbalance between the production of ROS and the ability of the cellular antioxidant system to readily detoxify ROS led to oxidative stress [142,143]. Glutathione (GSH) is the most abundant intracellular antioxidant, and is involved in the protection of cells against oxidative damage and in various detoxification mechanisms [144]. Diminution of intracellular GSH levels results in the accumulation of ROS in cells, and elevated levels are associated with apoptosis resistance [145]. Nicotinamide adenine dinucleotide phosphate (NADPH) is an essential cofactor for the biosynthesis of GSH, and the oxidized form of glutathione, GSSG, is reduced to GSH in an NADPH-dependent reaction catalyzed by glutathione reductase [146].

IDH1 catalyzes the oxidative carboxylation of isocitrate to a-ketoglutarate, yielding reduced NADPH [141]. In gliomas, IDH1 mutations decreased the intracellular GSH levels, enhanced the levels of intracellular ROS and inhibited the growth of glioma cells [141]. Overexpression of mutant IDH1 in glioma cells resulted in an increase in intracellular ROS levels, showing that the mutant IDH1 affected growth inhibition by induction of cell apoptosis and inhibition of proliferation [128]. Thus, NADPH levels are diminished in IDH1-R132H gliomas in situ [136].

8. Hypoxia in IDH1-Mutated Glioma

Tumor hypoxia results in constitutive upregulation of glycolysis and acidosis, contributing to the tumor resistance of therapeutic agents [147]. The progression of gliomagenesis often occurs in a hypoxic microenvironment that compels the use of anaerobic glycolysis as the primary energy source [148]. Hypoxia stabilizes HIF, a transcription factor, which increases the biological aggressiveness of tumors, promoting glycolysis, cellular proliferation, and angiogenesis [149,150]. Once activated, HIF-1α can regulate the expression of many glycolytic enzymes including glucose transporters and mitochondrial enzymes that are involved in the metabolic adaptation to hypoxia through the conversion of glucose to pyruvate and subsequently to lactate [151]. Hypoxia in solid tumors plays an important role in the propagation of a cascade of molecular pathways in favor of tumor growth [152]. Hypoxia-induced HIFs stimulate angiogenesis and increase malignancy, metastasis, and resistance to therapy [153]. HIF-1α is one of the key factors that regulates the expression of VEGF, which plays an important role in angiogenesis in gliomas [154].

IDH1-related low-grade and anaplastic gliomas were not associated with an activation of HIF-1α and HIF-1α overexpression was restricted to necrotic areas [137,138,139]. IDH1 mutations and 2HG production were shown to inhibit prolyl-hydroxylase (PHD) enzymes, which inhibit HIF-1a, the major pro-angiogenic and pro-glycolysis transcription factor [155,156].

9. Aerobic Glycolysis and WNT/β-catenin Pathway in Glioma

Glucose is the major source of energy for mammalian cells. Glucose is metabolized to produce ATP (energy), through cytosolic glycolysis and oxygen-dependent mitochondrial metabolism. The entry of glucose into the TCA cycle is controlled by PDH (pyruvate dehydrogenase complex). Inhibition of PDH inactivates mitochondrial activity in gliomas [157]. A large part of the glucose supply is fermented to lactate; this phenomenon is called aerobic glycolysis or the Warburg effect [158].

Growing evidence reveals that all cancers, regardless of tissue or cellular origin, are a disease of impaired cellular energy metabolism [159]. In addition to the previously well recognized hallmarks of cancers [160,161,162], aerobic glycolysis is also a robust metabolic feature of most tumors [160,163,164]. Recent studies on gliomas in experimental models show the dependence of glioma cells on glycolysis as the primary source of energy [165]. Glioma cells are dependent on glycolysis for their primary source of energy [165], with upregulation of glycolytic metabolism [166,167]. Cancer cells can use aerobic glycolysis at all oxygen levels (i.e., normoxia, hypoxia, or hyperbaric oxygen) [168].

10. Normoxia and WNT/β-catenin Pathway Upregulation in Glioma

In cancer cells, early overexpression of the WNT/β-catenin pathway leads to induce aerobic glycolysis [169] (Figure 2).

In addition, WNT target genes, c-Myc and cyclin D1, also activate aerobic glycolysis [170]. c-Myc and PI3K/Akt signaling overexpression induces HIF-1α activation, which suppresses glucose entry into the TCA cycle [171,172]. Activation of canonical WNT signaling directly acts on aerobic glycolysis [173] and increases vessel development via the WNT target genes [174]. Activation of the canonical WNT/β-catenin pathway suppresses oxidative metabolism into the TCA cycle and promotes cell proliferation [174]. The WNT pathway induces the transcription of genes implicated in cell proliferation, c-Myc (through glutaminolysis, nucleotide synthesis and lactate dehydrogenase-A (LDH-A) activation) and cyclin-D1 (through G1) [170,175,176,177,178,179]. The WNT target gene c-Myc drives aerobic glycolysis and glutaminolysis [171,177]. c-Myc induces glutamine uptake into the cell and the mitochondria and favors aspartate synthesis [170].

WNT/β-catenin pathway stimulates RTK (such as PI3K signaling) activation in gliomas [180]. Downregulation of β-catenin reduces the expression of EGFR, Akt signaling and their downstream genes [181,182,183,184]. Aerobic glycolysis also occurs via PI3K/Akt signaling in cancer cells, glucose is taken up in excess and rewired towards protein and lipid synthesis [185,186,187], which induces cellular growth. Hyper activation of PI3K/Akt pathway is associated with an increased rate of glucose metabolism [188]. Under normoxic conditions, activation of the qPI3K/Akt pathway results in HIF-1α stimulation [189].

Phosphorylated STAT3 by IL-6 (interleukin 6) or LIF (leukemia inhibitory factor) is associated with overexpression of HIF-1α under normoxic conditions [190]. Β-catenin/TCF4 complex directly binds to the STAT3 gene promoter [191]. STAT pathways participate in tumorigenesis through up-regulation of genes encoding cell-cycle regulators (cyclin D1, c-Myc) and induces activation of VEGF [192].

It has been reported that HIF-1α can be activated by numerous oncogenes even under normoxic conditions (independent of hypoxia) [186,193,194,195]. HIF-1α is induced transcriptionally by PI3K/mTOR even under normoxic conditions through 4E-BP1 and STAT3 [190,196,197,198,199,200]. PI3K activates mTORC1 through Akt which inhibits by phosphorylation the tuberous sclerosis complex (TSC) [201,202]. mTOR-mediated HIF-1α induction mimics the effect of hypoxia and then leads to glycolysis [189]. Several genetic mutations (such as mutated genes encoding PDGFR, EGFR, p53, and PTEN) result in HIF-1α stabilization resulting in increased angiogenesis by upregulation of angiogenic factors [203,204,205,206,207]. HIF-1α activated initiates the transcription of target genes including glucose transporters, the MCT-4 and key pro-angiogenic effectors such as VEGF [149,208]. HIF-1α also promotes both glycolytic energy metabolism and angiogenesis and participates in the poor cancer prognosis [209,210].

c-Myc overexpression can also enhance LDH-A expression by promoting HIF-1α stabilization under normoxic conditions [211]. c-Myc cooperates with HIF-1α in activating several genes that encode glycolytic proteins, such as LDH-A [212]. LDH-A activation is associated with activation of the VEGF pathway [213,214,215,216].

Cancers cells use LDH-A to elevate the rate of glycolysis, ATP and lactate production [217]. HIF-1α and c-Myc are the major transcription factors of LDH-A [218,219,220,221]. Overexpression of HIF-1α is associated with LDH-A overexpression and poor survival in many cancers [215,222]. LDH-A activation is associated with activation of the VEGF pathway [213,214,215,216]. A high level of cytoplasmic LDH-A is correlated with cytoplasmic VEGF expression [215]. This association could be partly due to transcription factors HIF-1α and c-Myc [211]. Lactate plays an important role in angiogenesis, by stimulation of VEGF [223,224,225]. In gliomas, lactate also triggers HIF-1α activation in a hypoxia-independent manner by inhibition of HIF-1α proline hydroxylation [226]. Lactate stimulates HIF-1α activity in normoxic endothelial cells resulting in an increase of pro-angiogenic targets such as VEGFR2 [227]. VEGFR2 is the main transducer of pro-angiogenic effects of VEGF [228]. Lactate that arose from aerobic glycolysis induces the VEGF/VEGFR2 signaling pathway in a hypoxia-independent manner [229]. Acute acidic extracellular pH, which can be caused by elevated lactate production, was shown to promote upregulation of IL-8 and VEGF independently of hypoxia [230,231,232,233,234,235]. Lactate overexpression promotes angiogenesis [236] and increased extracellular lactate concentrations activates the VEGF pathway [237]. VEGF expression in glioma cells is independently regulated by pH and tissue pO2 [231]. Hypoxia and acidic pH have no synergistic effect on VEGF transcription [231].

11. Conclusions

The majority of IDH wild-type glioblastomas refer to primary glioblastomas which occur in elderly patients and develop de novo. IDH-wild-type glioblastomas usually present short clinical history, without a pre-existing lower-grade precursor lesion. They are characterized by the upregulation of the WNT/β-catenin pathway showing an early tumor development under normoxic conditions for the main part [129]. In contrast, IDH mutant glioblastomas are typically observed in young adults and include the majority of secondary glioblastomas developed by the progression from a pre-existing diffuse or anaplastic astrocytoma [238]. The distinction of “IDH wild-type/WNT upregulated” and “IDH mutant/WNT downregulated” glioblastomas is major as these differences are not only biologically distinct subtypes but also associated with different clinical presentations, such as age and survival rate, with significantly shorter overall survival observed in patients with “IDH wild-type/WNT upregulated” glioblastoma [28]. Thus, opposed WNT/β-catenin pathway expression is observed between IDH wild-type and IDH mutant glioblastomas and this could be included in gliomas classification (Figure 3).

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/biomedicines9060619/s1.

Click here for additional data file.

Author Contributions

Conceptualization, A.V. and J.-N.V.; validation, A.V., Y.L. and J.-N.V.; writing—original draft preparation, A.V.; writing—review and editing, Y.L. and J.-N.V.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Figure 1 The WNT/β-catenin pathway and its different actions in gliomas processes. When the canonical WNT/β-catenin pathway is stimulated, STAT3 signaling pathway upregulates the expression and transcriptional activity of β-catenin. In cancers STAT3 is a tumor aggressiveness factor. In cancers, the overexpression of EGFR (a receptor tyrosine kinase: RTK) stimulates PI3K/Akt pathway. PI3K/Akt signaling leads to the phosphorylation of GSK-3β that leads to nuclear translocation and stabilization of β-catenin. Similarly, WNT/β-catenin pathway stimulates EGFR in gliomas. Akt signaling increases MMP-2 and MMP-9 activity, which induce invasion of cancer cells. Akt signaling induces HIF-1a, which stimulates PDK1. Overexpression of WNT/β-catenin also stimulates PDK1. PDK1 and c-Myc induce LDH-A, and cytolsolic pyruvate is shunted into lactate through activation of LDH-A. Overexpression of MCT-1 exports lactate to extracellular space. Lactate production stimulates angiogenesis. c-Myc induced glutaminolysis supports mitochondrial integrity and production of aspartate, and results in nucleotide biosynthesis. c-Myc and cyclin D stimulate proliferation of gliomas.

Figure 2 The WNT/β-catenin pathway and the Warburg effect (i.e., aerobic glycolysis). WNT ligands bind the complex Frizzled/LRP 5/6 receptors leading to LRP phosphorylation of the AXIN/APC/GSK-3β complex. β-catenin phosphorylation is inhibited and this prevents its degradation in the proteasome. β-catenin accumulates into the cytosol and then translocates to the nucleus to bind TCF-LEF co transcription factors. WNT-response gene transcription is stimulated (PDK, c-Myc, cyclin D, MCT-1). MCT-1 promotes the release of lactate out of the cell. WNT/β-catenin pathway activates tyrosine kinase receptors (TKRs). Activation of PI3K/Akt increases glucose metabolism. Akt-transformed cells induce HIF-1α stabilization, which largely diminishes the glucose entry into the TCA cycle. Stimulated HIF-1α activity increases expression of glycolytic enzymes (GLUT, HK, PKM2, LDH-A). Elevated aerobic glycolysis is observed with increased production of lactate and decreased mitochondrial respiration. HIF-1α induced PDK phosphorylates PDH, which results in cytosolic pyruvate being shunted into lactate through induction of LDH-A. PDK inhibits the PDH complex into mitochondria. Thus, pyruvate cannot be fully converted into acetyl-CoA and enter the TCA cycle. c-Myc and cyclin D also activate LDH-A, which converts cytosolic pyruvate into lactate. Activated PKM2 translocates to the nucleus through Pin1, then binds β-catenin and induces c-Myc expression. This activates GLUT, PKM2 and LDH-A in a positive feedback.

Figure 3 Features of diffuse glioma. In the 2016 WHO classification, diffuse astrocytic tumors and oligodendrogliomas can be defined by mutually exclusive genotypes (astrocytic, TP53 mt/ATRX mt; oligodendroglial, 1p/19q-codel/TERT mt) under the shared IDH mutation. IDH-wildtype tumors represent the main malignant glioblastoma or diffuse glioma genetically corresponding to glioblastoma. Our hypothesis is to add to this classification the notion of WNT pathway expression. IDH-mutant presents downregulation of the WNT pathway whereas IDH-wild-type presents upregulation of the WNT pathway. WNT pathway stimulation in the early stages of the tumor process is associated with normoxic glioma development with early angiogenesis process.

biomedicines-09-00619-t001_Table 1 Table 1 Opposed interplay between the WNT pathway and IDH1 mutations and the involved molecular targets.

Marker	Cell Pathways	Regulation	Subtypes	Prognosis	References	
IDH1 mutations	NADPH-dependent reduction of alpha-ketoglutarate	HIF-1α reduction activity	Glioblastoma	Good survival rate	[136]	
IDH1 mutations	TP 53 and total 1p/19q deletions	-	Oligodendroglia tumors	Good survival rate	[26]	
IDH1-R132H mutation	β-catenin, TCF4 and LEF1 downregulation	Decrease WNT signaling	Glioma cells	Lower invasion	[126,134]	
IDH1-R132H mutation	PI3K/Akt pathway decrease	Decrease WNT signaling	Glioma cells	Good survival rate	[131,132,133]	
IDH1 mutations	HIF-1α reduction activity	Decrease WNT signaling	Restricted to necrotic areas	Poor survival rate	[137,138,139]	
EGFR	β-catenin accumulation	Increase WNT signaling	Astrocytomas	Glioma progression and invasion	[98,99,101,102,103,104,105]	
sFRP1 depletion	β-catenin accumulation	Increase WNT signaling	Glioblastoma	Inhibit Motility and Promote Growth	[112,113]	
RTKs	WNT signaling	IDH1 decrease	Glioblastoma		[45]	

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Furnari F.B. Fenton T. Bachoo R.M. Mukasa A. Stommel J.M. Stegh A. Hahn W.C. Ligon K.L. Louis D.N. Brennan C. Malignant astrocytic glioma: Genetics, biology, and paths to treatment Genes Dev. 2007 21 2683 2710 10.1101/gad.1596707 17974913
2. Gladson C.L. Prayson R.A. Liu W. (Michael) The Pathobiology of Glioma Tumors Annu. Rev. Pathol. Mech. Dis. 2010 5 33 50 10.1146/annurev-pathol-121808-102109 19737106
3. Louis D.N. Perry A. Reifenberger G. Von Deimling A. Figarella-Branger D. Cavenee W.K. Ohgaki H. Wiestler O.D. Kleihues P. Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary Acta Neuropathol. 2016 131 803 820 10.1007/s00401-016-1545-1 27157931
4. Kristensen B. Priesterbach-Ackley L. Petersen J. Wesseling P. Molecular pathology of tumors of the central nervous system Ann. Oncol. 2019 30 1265 1278 10.1093/annonc/mdz164 31124566
5. Parsons D.W. Jones S. Zhang X. Lin J.C.-H. Leary R.J. Angenendt P. Mankoo P. Carter H. Siu I.-M. Gallia G.L. An Integrated Genomic Analysis of Human Glioblastoma Multiforme Science 2008 321 1807 1812 10.1126/science.1164382 18772396
6. Arita H. Narita Y. Yoshida A. Hashimoto N. Yoshimine T. Ichimura K. IDH1/2 mutation detection in gliomas Brain Tumor Pathol. 2014 32 79 89 10.1007/s10014-014-0197-x 25008158
7. Liu Y. Lang F. Chou F.-J. Zaghloul K.A. Yang C. Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications Biomedicines 2020 8 294 10.3390/biomedicines8090294
8. Ülgen E. Karacan S. Gerlevik U. Can O. Bilguvar K. Oktay Y. Akyerli C.B. Yüksel Ş.K. Danyeli A.E. Tihan T. Mutations and Copy Number Alterations in IDH Wild-Type Glioblastomas Are Shaped by Different Oncogenic Mechanisms Biomedicines 2020 8 574 10.3390/biomedicines8120574
9. Brennan C. Momota H. Hambardzumyan D. Ozawa T. Tandon A. Pedraza A. Holland E. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations PLoS ONE 2009 4 e7752 10.1371/journal.pone.0007752 19915670
10. Gong A. Huang S. FoxM1 and Wnt/β-Catenin Signaling in Glioma Stem Cells Cancer Res. 2012 72 5658 5662 10.1158/0008-5472.CAN-12-0953 23139209
11. Yu C.-Y. Liang G.-B. Du P. Liu Y.-H. Lgr4 Promotes Glioma Cell Proliferation through Activation of Wnt Signaling Asian Pac. J. Cancer Prev. 2013 14 4907 4911 10.7314/APJCP.2013.14.8.4907 24083766
12. Lee Y. Lee J.-K. Ahn S.H. Lee J. Nam D.-H. WNT signaling in glioblastoma and therapeutic opportunities Lab. Investig. 2015 96 137 150 10.1038/labinvest.2015.140 26641068
13. Tao B. Song Y. Wu Y. Yang X. Peng T. Peng L. Xia K. Xia X. Chen L. Zhong C. Matrix stiffness promotes glioma cell stemness by activating BCL9L/Wnt/β-catenin signaling Aging 2021 13 5284 5296 10.18632/aging.202449 33535177
14. Schwartzentruber J. Korshunov A. Liu X.-Y. Jones D.T.W. Pfaff E. Jacob K. Sturm D. Fontebasso A.M. Quang D.-A.K. Tönjes M. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nat. Cell Biol. 2012 482 226 231 10.1038/nature10833
15. Sturm D. Witt H. Hovestadt V. Khuong-Quang D.-A. Jones D.T.W. Konermann C. Pfaff E. Tönjes M. Sill M. Bender S. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma Cancer Cell 2012 22 425 437 10.1016/j.ccr.2012.08.024 23079654
16. Wu G. Broniscer A. McEachron T.A. Lu C. Paugh B.S. Becksfort J. Qu C. Ding L. Huether R. Parker M. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas Nat. Genet. 2012 44 251 253 22286216
17. Agnihotri S. Aldape K.D. Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma Neurosurg. Focus 2014 37 E13 10.3171/2014.9.FOCUS14505 25434382
18. Balss J. Meyer J. Mueller W. Korshunov A. Hartmann C. Von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol. 2008 116 597 602 10.1007/s00401-008-0455-2 18985363
19. Nobusawa S. Watanabe T. Kleihues P. Ohgaki H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas Clin. Cancer Res. 2009 15 6002 6007 10.1158/1078-0432.CCR-09-0715 19755387
20. Watanabe T. Nobusawa S. Kleihues P. Ohgaki H. IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas Am. J. Pathol. 2009 174 1149 1153 10.2353/ajpath.2009.080958 19246647
21. Ducray F. Marie Y. Sanson M. IDH1 and IDH2 Mutations in Gliomas N. Engl. J. Med. 2009 360 2248 2249 author reply 2249 19469031
22. Songtao Q. Lei Y. Si G. Yanqing D. Huixia H. Xuelin Z. Lanxiao W. Fei Y. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma Cancer Sci. 2012 103 269 273 10.1111/j.1349-7006.2011.02134.x 22034964
23. Tesileanu C.M.S. Dirven L. Wijnenga M.M.J. Koekkoek J.A.F. Vincent E.A.J.P. Dubbink H.J. Atmodimedjo P.N. Kros J.M. van Duinen S.G. Smits M. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: A confirmation of the cIMPACT-NOW criteria Neuro-Oncology 2020 22 515 523 10.1093/neuonc/noz200 31637414
24. Franceschi E. De Biase D. Di Nunno V. Pession A. Tosoni A. Gatto L. Tallini G. Visani M. Lodi R. Bartolini S. IDH1 Non-Canonical Mutations and Survival in Patients with Glioma Diagnostics 2021 11 342 10.3390/diagnostics11020342 33669525
25. Ludwig K. Kornblum H.I. Molecular markers in glioma J. Neuro-Oncology 2017 134 505 512 10.1007/s11060-017-2379-y 28233083
26. Ichimura K. Pearson D.M. Kocialkowski S. Bäcklund L.M. Chan R. Jones D.T.W. Collins V.P. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas Neuro-Oncology 2009 11 341 347 10.1215/15228517-2009-025 19435942
27. Aldape K. Zadeh G. Mansouri S. Reifenberger G. Von Deimling A. Glioblastoma: Pathology, molecular mechanisms and markers Acta Neuropathol. 2015 129 829 848 10.1007/s00401-015-1432-1 25943888
28. Weller M. Felsberg J. Hartmann C. Berger H. Steinbach J.P. Schramm J. Westphal M. Schackert G. Simon M. Tonn J.C. Molecular Predictors of Progression-Free and Overall Survival in Patients with Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network J. Clin. Oncol. 2009 27 5743 5750 10.1200/JCO.2009.23.0805 19805672
29. Ohgaki H. Burger P. Kleihues P. Definition of Primary and Secondary Glioblastoma—Response Clin. Cancer Res. 2014 20 2013 10.1158/1078-0432.CCR-14-0238 24557936
30. Jones D.T.W. Jäger N. Kool M. Zichner T. Hutter B. Sultan M. Cho Y.-J. Pugh T.J. Hovestadt V. Stütz A.M. Dissecting the genomic complexity underlying medulloblastoma Nat. Cell Biol. 2012 488 100 105 10.1038/nature11284
31. Jones D.T.W. Hutter B. Jäger N. Korshunov A. Kool M. Warnatz H.-J. Zichner T. Lambert S.R. Ryzhova M. Quang D.A.K. Recurrent Somatic Alterations of FGFR1 and NTRK2 in Pilocytic Astrocytoma Nat. Genet. 2013 45 927 932 10.1038/ng.2682 23817572
32. Northcott P.A. Shih D.J.H. Peacock J. Garzia L. Morrissy A.S. Zichner T. Stütz A.M. Korshunov A. Reimand J. Schumacher S.E. Subgroup-specific structural variation across 1,000 medulloblastoma genomes Nat. Cell Biol. 2012 488 49 56 10.1038/nature11327
33. Bhavya B. Anand C.R. Madhusoodanan U.K. Rajalakshmi P. Krishnakumar K. Easwer H.V. Deepti A.N. Gopala S. To be wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma Cell. Mol. Neurobiol. 2019 40 53 63 10.1007/s10571-019-00730-3 31485826
34. Dubbink H.J. Taal W. Van Marion R. Kros J.M. Van Heuvel I. Bromberg J.E. Zonnenberg B.A. Zonnenberg C.B.L. Postma T.J. Gijtenbeek J.M.M. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 2009 73 1792 1795 10.1212/WNL.0b013e3181c34ace 19933982
35. Hartmann C. Hentschel B. Wick W. Capper D. Felsberg J. Simon M. Westphal M. Schackert G. Meyermann R. Pietsch T. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas Acta Neuropathol. 2010 120 707 718 10.1007/s00401-010-0781-z 21088844
36. Gorovets D. Kannan K. Shen R. Kastenhuber E.R. Islamdoust N. Campos C. Pentsova E. Heguy A. Jhanwar S.C. Mellinghoff I.K. IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma Clin. Cancer Res. 2012 18 2490 2501 10.1158/1078-0432.CCR-11-2977 22415316
37. Tan A.C. Ashley D.M. López G.Y. Malinzak M. Friedman H.S. Khasraw M. Management of glioblastoma: State of the art and future directions CA Cancer J. Clin. 2020 70 299 312 10.3322/caac.21613 32478924
38. Franceschi E. De Biase D. Di Nunno V. Pession A. Tosoni A. Gatto L. Lodi R. Tallini G. Visani M. Bartolini S. IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas Pathol. Res. Pract. 2021 221 153445 10.1016/j.prp.2021.153445 33887545
39. Tesileanu C.M.S. Vallentgoed W.R. Sanson M. Taal W. Clement P.M. Wick W. Brandes A.A. Baurain J.F. Chinot O.L. Wheeler H. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations Acta Neuropathol. 2021 141 945 957 10.1007/s00401-021-02291-6 33740099
40. Kessler J. Hohmann T. Güttler A. Petrenko M. Ostheimer C. Hohmann U. Bache M. Dehghani F. Vordermark D. Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms Cancers 2019 11 889 10.3390/cancers11060889
41. Gülten G. Yalçın N. Baltalarlı B. Doğu G. Acar F. Doğruel Y. The importance of IDH1, ATRX and WT-1 mutations in glioblastoma Pol. J. Pathol. 2020 71 127 137 10.5114/pjp.2020.97020 32729303
42. Weller M. Weber R. Willscher E. Riehmer V. Hentschel B. Kreuz M. Felsberg J. Beyer U. Löffler-Wirth H. Kaulich K. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups Acta Neuropathol. 2015 129 679 693 10.1007/s00401-015-1409-0 25783747
43. Ceccarelli M. Barthel F. Malta T.M. Sabedot T.S. Salama S. Murray B.A. Morozova O. Newton Y. Radenbaugh A. Pagnotta S.M. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma Cell 2016 164 550 563 10.1016/j.cell.2015.12.028 26824661
44. Cancer Genome Atlas Research NetworkBrat D.J. Verhaak R.G.W. Aldape K.D. Yung W.K.A. Salama S.R. Cooper L.A.D. Rheinbay E. Miller C.R. Vitucci M. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas N. Engl. J. Med. 2015 372 2481 2498 10.1056/nejmoa1402121 26061751
45. Verhaak R.G. Hoadley K.A. Purdom E. Wang V. Qi Y. Wilkerson M.D. Miller C.R. Ding L. Golub T. Mesirov J.P. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 2010 17 98 110 10.1016/j.ccr.2009.12.020 20129251
46. Babic I. Anderson E.S. Tanaka K. Guo D. Masui K. Li B. Zhu S. Gu Y. Villa G.R. Akhavan D. EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer Cell Metab. 2013 17 1000 1008 10.1016/j.cmet.2013.04.013 23707073
47. Ciriello G. Miller M.L. Aksoy B.A. Senbabaoglu Y. Schultz N. Sander C. Emerging landscape of oncogenic signatures across human cancers Nat. Genet. 2013 45 1127 1133 10.1038/ng.2762 24071851
48. Tsai Y.-L. Chang H.-H. Chen Y.-C. Chang Y.-C. Tsai Y.C.A.W.-C. Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance Biomedicines 2020 8 339 10.3390/biomedicines8090339
49. Karsy M. Neil J.A. Guan J. Mahan M.A. Colman H. Jensen R.L. A practical review of prognostic correlations of molecular biomarkers in glioblastoma Neurosurg. Focus 2015 38 E4 10.3171/2015.1.FOCUS14755
50. Zoncu R. Efeyan A. Sabatini D.M. mTOR: From growth signal integration to cancer, diabetes and ageing Nat. Rev. Mol. Cell Biol. 2010 12 21 35 10.1038/nrm3025 21157483
51. Seshacharyulu P. Ponnusamy M.P. Haridas D. Jain M. Ganti A.K. Batra S.K. Targeting the EGFR signaling pathway in cancer therapy Expert Opin. Ther. Targets 2012 16 15 31 10.1517/14728222.2011.648617 22239438
52. Vogt P.K. Hart J. PI3K and STAT3: A New Alliance Cancer Discov. 2011 1 481 486 10.1158/2159-8290.CD-11-0218 22348200
53. Paw I. Carpenter R.C. Watabe K. Debinski W. Lo H.-W. Mechanisms regulating glioma invasion Cancer Lett. 2015 362 1 7 10.1016/j.canlet.2015.03.015 25796440
54. Sami A. Karsy M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: Novel therapeutic agents and advances in understanding Tumor Biol. 2013 34 1991 2002 10.1007/s13277-013-0800-5
55. Vanhaesebroeck B. Stephens L. Hawkins P.T. PI3K signalling: The path to discovery and understanding Nat. Rev. Mol. Cell Biol. 2012 13 195 203 10.1038/nrm3290 22358332
56. Manning B.D. Cantley L.C. AKT/PKB Signaling: Navigating Downstream Cell 2007 129 1261 1274 10.1016/j.cell.2007.06.009 17604717
57. Mao H. Lebrun D.G. Yang J. Zhu V.F. Li M. Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets Cancer Investig. 2012 30 48 56 10.3109/07357907.2011.630050 22236189
58. Nikiforova M.N. Hamilton R.L. Molecular diagnostics of gliomas Arch. Pathol. Lab. Med. 2011 135 558 568 10.5858/2010-0649-RAIR.1 21526954
59. Masui K. Mischel P.S. Reifenberger G. Molecular classification of gliomas Handb. Clin. Neurol. 2016 134 97 120 10.1016/b978-0-12-802997-8.00006-2 26948350
60. Yang W. Xia Y. Hawke D. Li X. Liang J. Xing D. Aldape K. Hunter T. Yung W.A. Lu Z. PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis Cell 2012 150 685 696 10.1016/j.cell.2012.07.018 22901803
61. Phillips H.S. Kharbanda S. Chen R. Forrest W.F. Soriano R.H. Wu T.D. Misra A. Nigro J.M. Colman H. Soroceanu L. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006 9 157 173 10.1016/j.ccr.2006.02.019 16530701
62. Clarke I.D. Dirks P.B. A human brain tumor-derived PDGFR-α deletion mutant is transforming Oncogene 2003 22 722 733 10.1038/sj.onc.1206160 12569364
63. Smith J.S. Wang X.-Y. Qian J. Hosek S.M. Scheithauer B.W. Jenkins R.B. James C.D. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features J. Neuropathol. Exp. Neurol. 2000 59 495 503 10.1093/jnen/59.6.495 10850862
64. Lokker A.N. Sullivan C.M. Hollenbach S.J. Israel A.M. Giese A.N. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors Cancer Res. 2002 62 3729 3735 12097282
65. Assanah M. Lochhead R. Ogden A. Bruce J. Goldman J. Canoll P. Glial Progenitors in Adult White Matter Are Driven to Form Malignant Gliomas by Platelet-Derived Growth Factor-Expressing Retroviruses J. Neurosci. 2006 26 6781 6790 10.1523/JNEUROSCI.0514-06.2006 16793885
66. Loh K.M. van Amerongen R. Nusse R. Generating Cellular Diversity and Spatial Form: Wnt Signaling and the Evolution of Multicellular Animals Dev. Cell 2016 38 643 655 10.1016/j.devcel.2016.08.011 27676437
67. Oren O. Smith B.D. Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways Stem Cell Rev. Rep. 2017 13 17 23 10.1007/s12015-016-9691-3 27730468
68. Al-Harthi L. Wnt/β-catenin and its Diverse Physiological Cell Signaling Pathways in Neurodegenerative and Neuropsychiatric Disorders J. Neuroimmune Pharmacol. 2012 7 725 730 10.1007/s11481-012-9412-x 23114888
69. Marchetti B. Pluchino S. Wnt your brain be inflamed? Yes, it Wnt! Trends Mol. Med. 2013 19 144 156 10.1016/j.molmed.2012.12.001 23312954
70. LeCarpentier Y. Claes V. Duthoit G. Hébert J.-L. Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction Front. Physiol. 2014 5 429 10.3389/fphys.2014.00429 25414671
71. LeCarpentier Y. Vallée A. Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis Front. Neurol. 2016 7 100 10.3389/fneur.2016.00100 27445967
72. Vallée A. LeCarpentier Y. Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma Front. Neurosci. 2016 10 459 10.3389/fnins.2016.00459 27807401
73. Vallée A. LeCarpentier Y. Guillevin R. Vallée J.-N. Thermodynamics in Neurodegenerative Diseases: Interplay between Canonical WNT/Beta-Catenin Pathway–PPAR Gamma, Energy Metabolism and Circadian Rhythms Neuromolecular Med. 2018 20 174 204 10.1007/s12017-018-8486-x 29572723
74. Vallée A. Vallée J.-N. Lecarpentier Y. Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway Cells 2021 10 230 10.3390/cells10020230 33503974
75. He T.C. Sparks A.B. Rago C. Hermeking H. Zawel L. da Costa L.T. Morin P.J. Vogelstein B. Kinzler K.W. Identifi-cation of C-MYC as a Target of the APC Pathway Science 1998 281 1509 1512 10.1126/science.281.5382.1509 9727977
76. Shtutman M. Zhurinsky J. Simcha I. Albanese C. D’Amico M. Pestell R. Ben-Ze’ev A. The Cyclin D1 Gene Is a Target of the Beta-Catenin/LEF-1 Pathway Proc. Natl. Acad. Sci. USA 1999 96 5522 5527 10.1073/pnas.96.10.5522 10318916
77. Angers S. Moon R.T. Proximal events in Wnt signal transduction Nat. Rev. Mol. Cell Biol. 2009 10 468 477 10.1038/nrm2717 19536106
78. Sharma C. Pradeep A. Wong L. Rana A. Rana B. Peroxisome Proliferator-activated Receptor γ Activation Can Regulate β-Catenin Levels via a Proteasome-mediated and Adenomatous Polyposis Coli-independent Pathway J. Biol. Chem. 2004 279 35583 35594 10.1074/jbc.M403143200 15190077
79. Rosi M.C. Luccarini I. Grossi C. Fiorentini A. Spillantini M.G. Prisco A. Scali C. Gianfriddo M. Caricasole A. Terstappen G.C. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease J. Neurochem. 2010 112 1539 1551 10.1111/j.1471-4159.2009.06566.x 20050968
80. Clevers H. Nusse R. Wnt/β-Catenin Signaling and Disease Cell 2012 149 1192 1205 10.1016/j.cell.2012.05.012 22682243
81. Inestrosa N.C. Montecinos-Oliva C. Fuenzalida M. Wnt Signaling: Role in Alzheimer Disease and Schizophrenia J. Neuroimmune Pharmacol. 2012 7 788 807 10.1007/s11481-012-9417-5 23160851
82. Vallée A. LeCarpentier Y. Guillevin R. Vallée J.-N. Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis Oncotarget 2017 8 90579 90604 10.18632/oncotarget.21234 29163854
83. Vallée A. Lecarpentier Y. Vallée J.-N. Hypothesis of Opposite Interplay between the Canonical WNT/beta-catenin Pathway and PPAR Gamma in Primary Central Nervous System Lymphomas Curr. Issues Mol. Biol. 2019 31 1 20 10.21775/cimb.031.001 30647194
84. Aberle H. Bauer A. Stappert J. Kispert A. Kemler R. β-catenin is a target for the ubiquitin–proteasome pathway EMBO J. 1997 16 3797 3804 10.1093/emboj/16.13.3797 9233789
85. Wu D. Pan W. GSK3: A Multifaceted Kinase in Wnt Signaling Trends Biochem. Sci. 2010 35 161 168 10.1016/j.tibs.2009.10.002 19884009
86. Hur E.-M. Zhou F.-Q. GSK3 signalling in neural development Nat. Rev. Neurosci. 2010 11 539 551 10.1038/nrn2870 20648061
87. Ambacher K.K. Pitzul K.B. Karajgikar M. Hamilton A. Ferguson S.S. Cregan S.P. The JNK- and AKT/GSK3β- Signaling Pathways Converge to Regulate Puma Induction and Neuronal Apoptosis Induced by Trophic Factor Deprivation PLoS ONE 2012 7 e46885 10.1371/journal.pone.0046885 23056511
88. Orellana A.M.M. Vasconcelos A.R. Leite J.A. Lima L.D.S. Andreotti D.Z. Munhoz C.D. Kawamoto E. Scavone C. Age-related neuroinflammation and changes in AKT-GSK-3β and WNT/β-CATENIN signaling in rat hippocampus Aging 2015 7 1094 1108 10.18632/aging.100853 26647069
89. Wu J.-H. Zhang S.-H. Gao F.-J. Lei Y. Chen X.-Y. Zhang S.-J. Sun X.-H. RNAi screening identifies GSK3β as a regulator of DRP1 and the neuroprotection of lithium chloride against elevated pressure involved in downregulation of DRP1 Neurosci. Lett. 2013 554 99 104 10.1016/j.neulet.2013.08.057 24025791
90. Russo R. Adornetto A. Cavaliere F. Varano G.P. Rusciano D. Morrone L.A. Corasaniti M.T. Bagetta G. Nucci C. Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury Mol. Vis. 2015 21 718 729 26167113
91. Vallée A. LeCarpentier Y. Guillevin R. Vallée J.-N. Thermodynamics in Gliomas: Interactions between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma Front. Physiol. 2017 8 352 10.3389/fphys.2017.00352 28620312
92. Vallée A. LeCarpentier Y. Guillevin R. Vallée J.-N. Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas Neurosci. Bull. 2018 34 573 588 10.1007/s12264-018-0219-5 29582250
93. Vallée A. LeCarpentier Y. Vallée J.-N. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs Cells 2019 8 726 10.3390/cells8070726 31311204
94. Vallée A. Vallée J.-N. LeCarpentier Y. PPARγ agonists: Potential treatment for autism spectrum disorder by inhibiting the canonical WNT/β-catenin pathway Mol. Psychiatry 2019 24 643 652 10.1038/s41380-018-0131-4 30104725
95. Vallée A. Lecarpentier Y. Guillevin R. Vallée J.-N. The influence of circadian rhythms and aerobic glycolysis in autism spectrum disorder Transl. Psychiatry 2020 10 400 10.1038/s41398-020-01086-9 33199680
96. Vallée A. Vallée J.-N. Guillevin R. Lecarpentier Y. Riluzole: A therapeutic strategy in Alzheimer’s disease by targeting the WNT/β-catenin pathway Aging 2020 12 3095 3113 10.18632/aging.102830 32035419
97. Vallée A. Vallée J.-N. Warburg effect hypothesis in autism Spectrum disorders Mol. Brain 2018 11 1 10.1186/s13041-017-0343-6 29301575
98. Sareddy G.R. Panigrahi M. Challa S. Mahadevan A. Babu P.P. Activation of Wnt/β-catenin/Tcf signaling pathway in human astrocytomas Neurochem. Int. 2009 55 307 317 10.1016/j.neuint.2009.03.016 19576519
99. Utsuki S. Sato Y. Oka H. Tsuchiya B. Suzuki S. Fujii K. Relationship between the Expression of E-, N-cadherins and beta-catenin and Tumor Grade in Astrocytomas J. Neuro-Oncol. 2002 57 187 192 10.1023/A:1015720220602
100. Zhang Z.-Q. Chen H.-Q. Chen Y.-H. Cheng X.-F. [Significance of beta-catenin and Cyclin D1 express in glioma] Chin. J. Cell. Mol. Immunol. 2009 25 1010 1012
101. Denysenko T. Annovazzi L. Cassoni P. Melcarne A. Mellai M. Schiffer D. WNT/β-catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma Cancer Genom. Proteom. 2015 13 31 45
102. Liu X. Wang L. Zhao S. Ji X. Luo Y. Ling F. β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells Med. Oncol. 2010 28 608 614 10.1007/s12032-010-9476-5 20300972
103. Liu C. Tu Y. Sun X. Jiang J. Jin X. Bo X. Li Z. Bian A. Wang X. Liu D. Wnt/beta-Catenin pathway in human glioma: Expression pattern and clinical/prognostic correlations Clin. Exp. Med. 2010 11 105 112 10.1007/s10238-010-0110-9 20809334
104. Yang Z. Wang Y. Fang J. Chen F. Liu J. Wu J. Wang Y. Song T. Zeng F. Rao Y. Downregulation of WIF-1 by Hy-permethylation in Astrocytomas Acta Biochim. Biophys. Sin. 2010 42 418 425 10.1093/abbs/gmq037 20539942
105. Yang C. Iyer R.R. Yu A.C.H. Yong R.L. Park D.M. Weil R.J. Ikejiri B. Brady R.O. Lonser R.R. Zhuang Z. -Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas Proc. Natl. Acad. Sci. USA 2012 109 6963 6968 10.1073/pnas.1118754109 22505738
106. Sareddy G.R. Pratap U.P. Viswanadhapalli S. Venkata P.P. Nair B.C. Krishnan S.R. Zheng S. Gilbert A.R. Brenner A.J. Brann D.W. PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling Neuro-Oncol. Adv. 2019 1 10.1093/noajnl/vdz042
107. Portela M. Casas-Tintó S. New Cellular Dimensions on Glioblastoma Progression Neurosci. Insights 2020 15 2633105520923076 10.1177/2633105520923076 32548582
108. Xu A. Yang H. Gao K. Zhan Z. Song Z. Huang T. Song Y. Expression profiles and prognostic significance of WNT family members in glioma via bioinformatic analysis Biosci. Rep. 2020 40 10.1042/BSR20194255 32181818
109. Huo X.-Y. Zhang X.-Y. Yuan F. Zhao X.-Y. You B.-A. HOXB7 Promotes Proliferation and Metastasis of Glioma by Reg-ulating the Wnt/β-Catenin Pathway Eur. Rev. Med. Pharmacol. Sci. 2021 25 3146 10.26355/eurrev_202104_25708 33928593
110. Sun J. Ma Q. Shu C. Xiong J. Li B. Wu J. Zhang S. Li J. Liu J. Wang J. MicroRNA-301a/ZNRF3/wnt/β-catenin signal regulatory crosstalk mediates glioma progression Int. J. Oncol. 2020 58 45 56 10.3892/ijo.2020.5145 33367931
111. Shou J. Ali-Osman F. Multani A.S. Pathak S. Fedi P. Srivenugopal K.S. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA Oncogene 2002 21 878 889 10.1038/sj.onc.1205138 11840333
112. Roth W. Wild-Bode C. Platten M. Grimmel C. Melkonyan H.S. Dichgans J. Weller M. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells Oncogene 2000 19 4210 4220 10.1038/sj.onc.1203783 10980594
113. Delic S. Lottmann N. Stelzl A. Liesenberg F. Wolter M. Götze S. Zapatka M. Shiio Y. Sabel M.C. Felsberg J. MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation Neuro-Oncology 2013 16 179 190 10.1093/neuonc/not164 24305703
114. Jin X. Jeon H.-Y. Joo K.M. Kim J.-K. Jin J. Kim S.H. Kang B.G. Beck S. Lee S.J. Kim J.K. Frizzled 4 Regulates Stemness and Invasiveness of Migrating Glioma Cells Established by Serial Intracranial Transplantation Cancer Res. 2011 71 3066 3075 10.1158/0008-5472.CAN-10-1495 21363911
115. Huang P.H. Xu A.M. White F.M. Oncogenic EGFR Signaling Networks in Glioma Sci. Signal. 2009 2 re6 10.1126/scisignal.287re6 19738203
116. Karpel-Massler G. Schmidt U. Unterberg A. Halatsch M.-E. Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand? Mol. Cancer Res. 2009 7 1000 1012 10.1158/1541-7786.MCR-08-0479 19584260
117. Kang C. Chen L. Huang K. Han L. Shi Z. Zhang K. Pu P. Jiang C. Kang C. β-Catenin/Tcf-4 Complex transcriptionally regulates AKT1 in glioma Int. J. Oncol. 2011 39 883 890 10.3892/ijo.2011.1104 21720709
118. Kong D.-S. Song S.-Y. Kim D.-H. Joo K.M. Yoo J.-S. Koh J.S. Dong S.M. Suh Y.-L. Lee J.-I. Park K. Prognostic significance of c-Met expression in glioblastomas Cancer 2008 115 140 148 10.1002/cncr.23972 18973197
119. Nabeshima K. Shimao Y. Sato S. Kataoka H. Moriyama T. Kawano H. Wakisaka S. Koono M. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: An immunohistochemical study Histopathology 1997 31 436 443 10.1046/j.1365-2559.1997.3010889.x 9416484
120. Louis D.N. Molecular pathology of malignant gliomas Annu. Rev. Pathol. Mech. Dis. 2006 1 97 117 10.1146/annurev.pathol.1.110304.100043
121. Mizoguchi M. Betensky R.A. Batchelor T.T. Bernay D.C. Louis D.N. Nutt C.L. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival J. Neuropathol. Exp. Neurol. 2006 65 1181 1188 10.1097/01.jnen.0000248549.14962.b2 17146292
122. Organ S.L. Tsao M.-S. An overview of the c-MET signaling pathway Ther. Adv. Med. Oncol. 2011 3 S7 S19 10.1177/1758834011422556 22128289
123. Kessler J. Güttler A. Wichmann H. Rot S. Kappler M. Bache M. Vordermark D. IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status Radiother. Oncol. 2015 116 381 387 10.1016/j.radonc.2015.08.007 26328938
124. Anson M. Crain-Denoyelle A.-M. Baud V. Chereau F. Gougelet A. Terris B. Yamagoe S. Colnot S. Viguier M. Perret C. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice J. Clin. Investig. 2012 122 586 599 10.1172/JCI43937 22251704
125. Valenta T. Hausmann G. Basler K. The many faces and functions of β-catenin EMBO J. 2012 31 2714 2736 10.1038/emboj.2012.150 22617422
126. Cui D. Ren J. Shi J. Feng L. Wang K. Zeng T. Jin Y. Gao L. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling Int. J. Biochem. Cell Biol. 2016 73 72 81 10.1016/j.biocel.2016.02.007 26860959
127. Shi J. Sun B. Shi W. Zuo H. Cui D. Ni L. Chen J. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation Tumor Biol. 2014 36 655 662 10.1007/s13277-014-2644-z 25283382
128. Shi J. Zuo H. Ni L. Xia L. Zhao L. Gong M. Nie D. Gong P. Cui D. Shi W. An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation Neurol. Sci. 2013 35 839 845 10.1007/s10072-013-1607-2 24362902
129. Vallée A. Guillevin R. Vallée J.-N. Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/β-catenin pathway in gliomas Rev. Neurosci. 2017 29 71 91 10.1515/revneuro-2017-0032 28822229
130. Koul D. PTEN Signaling pathways in glioblastoma Cancer Biol. Ther. 2008 7 1321 1325 10.4161/cbt.7.9.6954 18836294
131. Birner P. Pusch S. Christov C. Mihaylova S. Ms K.T. Natchev S. Schoppmann S.F. Tchorbanov A. Streubel B. Tuettenberg J. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma Cancer 2014 120 2440 2447 10.1002/cncr.28732 24771584
132. Bleau A.-M. Hambardzumyan D. Ozawa T. Fomchenko E.I. Huse J.T. Brennan C.W. Holland E.C. PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells Cell Stem Cell 2009 4 226 235 10.1016/j.stem.2009.01.007 19265662
133. Huse J.T. Brennan C. Hambardzumyan D. Wee B. Pena J. Rouhanifard S.H. Sohn-Lee C. Le Sage C. Agami R. Tuschl T. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo Genes Dev. 2009 23 1327 1337 10.1101/gad.1777409 19487573
134. Yao Q. Cai G. Yu Q. Shen J. Gu Z. Chen J. Shi W. Shi J. IDH1 mutation diminishes aggressive phenotype in glioma stem cells Int. J. Oncol. 2017 52 270 278 10.3892/ijo.2017.4186 29115585
135. Mehrjardi N.Z. Hänggi D. Kahlert U.D. Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma Cell Death Dis. 2020 11 1 12 10.1038/s41419-020-03196-0 31911576
136. Bleeker F.E. Atai N.A. Lamba S. Jonker A. Rijkeboer D. Bosch K.S. Tigchelaar W. Troost D. Vandertop W.P. Bardelli A. The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma Acta Neuropathol. 2010 119 487 494 10.1007/s00401-010-0645-6 20127344
137. Metellus P. Colin C. Taieb D. Guedj E. Nanni-Metellus I. De Paula A.M. Colavolpe C. Fuentes S. Dufour H. Barrie M. IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients J. Neuro-Oncol. 2011 105 591 600 10.1007/s11060-011-0625-2
138. Williams S.C. Karajannis M.A. Chiriboga L. Golfinos J.G. Von Deimling A. Zagzag D. R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma Acta Neuropathol. 2011 121 279 281 10.1007/s00401-010-0790-y 21181477
139. Tchoghandjian A. Koh M.Y. Taieb D. Ganaha S. Powis G. Bialecki E. Graziani N. Figarella-Branger D. Metellus P. Hypoxia-associated factor expression in low-grade and anaplastic gliomas: A marker of poor outcome Oncotarget 2014 5 10.18632/oncotarget.8046
140. Zhang Z. Leonard S.S. Huang C. Vallyathan V. Castranova V. Shi X. Role of reactive oxygen species and MAPKs in vanadate-induced G2/M phase arrest Free Radic. Biol. Med. 2003 34 1333 1342 10.1016/S0891-5849(03)00145-X 12726921
141. Menon S.G. Goswami P.C. A redox cycle within the cell cycle: Ring in the old with the new Oncogene 2006 26 1101 1109 10.1038/sj.onc.1209895 16924237
142. Sharma V. Joseph C. Ghosh S. Agarwal A. Mishra M.K. Sen E. Kaempferol induces apoptosis in glioblastoma cells through oxidative stress Mol. Cancer Ther. 2007 6 2544 2553 10.1158/1535-7163.MCT-06-0788 17876051
143. Deng S. Yang Y. Han Y. Li X. Wang X. Li X. Zhang Z. Wang Y. UCP2 Inhibits ROS-Mediated Apoptosis in A549 under Hypoxic Conditions PLoS ONE 2012 7 e30714 10.1371/journal.pone.0030714 22292025
144. Guha P. Dey A. Sen R. Chatterjee M. Chattopadhyay S. Bandyopadhyay S.K. Intracellular GSH Depletion Triggered Mitochondrial Bax Translocation to Accomplish Resveratrol-Induced Apoptosis in the U937 Cell Line J. Pharmacol. Exp. Ther. 2010 336 206 214 10.1124/jpet.110.171983 20876229
145. Gottesman M.M. Fojo T. Bates S.E. Multidrug resistance in cancer: Role of ATP–dependent transporters Nat. Rev. Cancer 2002 2 48 58 10.1038/nrc706 11902585
146. Izawa S. Maeda K. Miki T. Mano J. Inoue Y. Kimura A. Importance of glucose-6-phosphate dehydrogenase in the adaptive response to hydrogen peroxide in Saccharomyces cerevisiae Biochem. J. 1998 330 811 817 10.1042/bj3300811 9480895
147. Gillies R.J. Gatenby R.A. Metabolism and Its Sequelae in Cancer Evolution and Therapy Cancer J. 2015 21 88 96 10.1097/PPO.0000000000000102 25815848
148. Gillies R.J. Gatenby R.A. Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis? J. Bioenerg. Biomembr. 2007 39 251 257 10.1007/s10863-007-9085-y 17624581
149. Semenza G.L. HIF-1: Upstream and downstream of cancer metabolism Curr. Opin. Genet. Dev. 2010 20 51 56 10.1016/j.gde.2009.10.009 19942427
150. Semenza G.L. Oxygen Sensing, Homeostasis, and Disease N. Engl. J. Med. 2011 365 537 547 10.1056/NEJMra1011165 21830968
151. Samanta D. Semenza G.L. Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors Biochim. Biophys. Acta Rev. Cancer. 2018 1870 15 22 10.1016/j.bbcan.2018.07.002 30006019
152. Wu G. Luo J. Rana J.S. Laham R. Sellke F.W. Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells Cardiovasc. Res. 2006 69 512 519 10.1016/j.cardiores.2005.09.019 16336951
153. Airley R.E. Mobasheri A. Hypoxic Regulation of Glucose Transport, Anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics Chemotherapy 2007 53 233 256 10.1159/000104457 17595539
154. Liang C. Guo S. Yang L. All-trans retinoic acid upregulates VEGF expression in glioma cells in vitro J. Biomed. Res. 2013 27 51 55 10.7555/jbr.27.20120048 23554794
155. Zhao S. Lin Y. Xu W. Jiang W. Zha Z. Wang P. Yu W. Li Z. Gong L. Peng Y. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 Science 2009 324 261 265 10.1126/science.1170944 19359588
156. Xu W. Yang H. Liu Y. Yang Y. Wang P. Kim S.-H. Ito S. Yang C. Wang P. Xiao M.-T. Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases Cancer Cell 2011 19 17 30 10.1016/j.ccr.2010.12.014 21251613
157. Jha M.K. Suk K. Pyruvate Dehydrogenase Kinase as a Potential Therapeutic Target for Malignant Gliomas Brain Tumor Res. Treat. 2013 1 57 63 10.14791/btrt.2013.1.2.57 24904893
158. Warburg O. On the Origin of Cancer Cells Science 1956 123 309 314 10.1126/science.123.3191.309 13298683
159. Maxwell P. Activation of the HIF pathway in cancer Curr. Opin. Genet. Dev. 2001 11 293 299 10.1016/S0959-437X(00)00193-3 11377966
160. Hanahan D. Weinberg R.A. Hallmarks of Cancer: The Next Generation Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
161. Cubuk C. Hidalgo M.R. Amadoz A. Pujana M.A. Mateo F. Herranz C. Carbonell-Caballero J. Dopazo J. Gene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape Cancer Res. 2018 78 6059 6072 10.1158/0008-5472.CAN-17-2705 30135189
162. Çubuk C. Hidalgo M.R. Amadoz A. Rian K. Salavert F. Pujana M.A. Mateo F. Herranz C. Carbonell-Caballero J. Dopazo J. Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models NPJ Syst. Biol. Appl. 2019 5 7 10.1038/s41540-019-0087-2 30854222
163. Seyfried T.N. Mukherjee P. Targeting energy metabolism in brain cancer: Review and hypothesis Nutr. Metab. 2005 2 30 10.1186/1743-7075-2-30
164. Ristow M. Oxidative metabolism in cancer growth Curr. Opin. Clin. Nutr. Metab. Care 2006 9 339 345 10.1097/01.mco.0000232892.43921.98 16778561
165. Maurer G.D. Brucker D.P. Bähr O. Harter P.N. Hattingen E. Walenta S. Mueller-Klieser W. Steinbach J.P. Rieger J. Differential utilization of ketone bodies by neurons and glioma cell lines: A rationale for ketogenic diet as experimental glioma therapy BMC Cancer 2011 11 315 10.1186/1471-2407-11-315 21791085
166. Mineura K. Yasuda T. Kowada M. Shishido F. Ogawa T. Uemura K. Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose Neurol. Res. 1986 8 164 168 10.1080/01616412.1986.11739749 2877410
167. Oudard S. Arvelo F. Miccoli L. Apiou F. Dutrillaux A.M. Poisson M. Dutrillaux B. Poupon M.F. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss Br. J. Cancer 1996 74 839 845 10.1038/bjc.1996.446 8826847
168. Constant J.S. Feng J.J. Zabel D.D. Yuan H. Suh D.Y. Scheuenstuhl H. Hunt T.K. Hussain M.Z. Lactate elicits vascular endothelial growth factor from macrophages: A possible alternative to hypoxia Wound Repair Regen. 2000 8 353 360 10.1111/j.1524-475X.2000.00353.x 11115148
169. Thompson C.B. Wnt meets Warburg: Another piece in the puzzle? EMBO J. 2014 33 1420 1422 10.15252/embj.201488785 24843042
170. Wise D.R. DeBerardinis R.J. Mancuso A. Sayed N. Zhang X.-Y. Pfeiffer H.K. Nissim I. Daikhin E. Yudkoff M. McMahon S.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction Proc. Natl. Acad. Sci. USA 2008 105 18782 18787 10.1073/pnas.0810199105 19033189
171. Kim J.-W. Gao P. Liu Y.-C. Semenza G.L. Dang C.V. Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 Mol. Cell. Biol. 2007 27 7381 7393 10.1128/MCB.00440-07 17785433
172. Lum J.J. Bui T. Gruber M. Gordan J.D. DeBerardinis R.J. Covello K.L. Simon M.C. Thompson C.B. The transcription factor HIF-1 plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis Genes Dev. 2007 21 1037 1049 10.1101/gad.1529107 17437992
173. Brabletz T. Hlubek F. Spaderna S. Schmalhofer O. Hiendlmeyer E. Jung A. Kirchner T. Invasion and Metastasis in Colorectal Cancer: Epithelial-Mesenchymal Transition, Mesenchymal-Epithelial Transition, Stem Cells and β-Catenin Cells Tissues Organs 2005 179 56 65 10.1159/000084509 15942193
174. Pate K.T. Stringari C. Sprowl-Tanio S. Wang K. TeSlaa T. Hoverter N.P. McQuade M. Garner C. Digman A.M. Teitell A.M. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer EMBO J. 2014 33 1454 1473 10.15252/embj.201488598 24825347
175. Chafey P. Finzi L. Boisgard R. Caüzac M. Clary G. Broussard C. Pégorier J.-P. Guillonneau F. Mayeux P. Camoin L. Proteomic analysis of β-catenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway Proteomics 2009 9 3889 3900 10.1002/pmic.200800609 19639598
176. Dang C.V. Rethinking the Warburg Effect with Myc Micromanaging Glutamine Metabolism Cancer Res. 2010 70 859 862 10.1158/0008-5472.CAN-09-3556 20086171
177. Moon R.T. The Promise and Perils of Wnt Signaling Through Beta-Catenin Science 2002 296 1644 1646 10.1126/science.1071549 12040179
178. Niehrs C. Acebron S.P. Mitotic and mitogenic Wnt signalling EMBO J. 2012 31 2705 2713 10.1038/emboj.2012.124 22617425
179. van de Wetering M. Sancho E. Verweij C. de Lau W. Oving I. Hurlstone A. van der Horn K. Batlle E. Coudreuse D. Haramis A.P. The Beta-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells Cell 2002 111 241 250 10.1016/S0092-8674(02)01014-0 12408868
180. Popescu A.M. Purcaru S.O. Alexandru O. Dricu A. New perspectives in glioblastoma antiangiogenic therapy Współczesna Onkol. 2016 20 109 118 10.5114/wo.2015.56122
181. Park K.S. Da Lee R. Kang S.-K. Han S.Y. Park K.L. Yang K.H. Song Y.S. Park H.J. Lee Y.M. Yun Y.P. Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway Exp. Cell Res. 2004 297 424 433 10.1016/j.yexcr.2004.03.034 15212945
182. Tan X. Apte U. Micsenyi A. Kotsagrelos E. Luo J.-H. Ranganathan S. Monga D.K. Bell A. Michalopoulos G.K. Monga S.P.S. Epidermal Growth Factor Receptor: A Novel Target of the Wnt/Beta-Catenin Pathway in Liver Gastroenterology 2005 129 285 302 10.1053/j.gastro.2005.04.013 16012954
183. Yue X. Lan F. Yang W. Yang Y. Han L. Zhang A. Liu J. Zeng H. Jiang T. Pu P. Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells Brain Res. 2010 1366 27 37 10.1016/j.brainres.2010.10.032 20969832
184. Zhang J. Huang K. Shi Z. Zou J. Wang Y. Jia Z. Zhang A. Han L. Yue X. Liu N. High -catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression Neuro-Oncology 2011 13 600 609 10.1093/neuonc/nor034 21636708
185. Elstrom R.L. Bauer D.E. Buzzai M. Karnauskas R. Harris M.H. Plas D.R. Zhuang H. Cinalli R.M. Alavi A. Rudin C.M. Akt Stimulates Aerobic Glycolysis in Cancer Cells Cancer Res. 2004 64 3892 3899 10.1158/0008-5472.CAN-03-2904 15172999
186. Hunt T.K. Aslam R.S. Beckert S. Wagner S. Ghani Q.P. Hussain M.Z. Roy S. Sen C.K. Aerobically Derived Lactate Stimulates Revascularization and Tissue Repair via Redox Mechanisms Antioxid. Redox Signal. 2007 9 1115 1124 10.1089/ars.2007.1674 17567242
187. Ward P. Thompson C.B. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate Cancer Cell 2012 21 297 308 10.1016/j.ccr.2012.02.014 22439925
188. Reuter S. Gupta S.C. Chaturvedi M.M. Aggarwal B.B. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic. Biol. Med. 2010 49 1603 1616 10.1016/j.freeradbiomed.2010.09.006 20840865
189. Sun Q. Chen X. Ma J. Peng H. Wang F. Zha X. Wang Y. Jing Y. Yang H. Chen R. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth Proc. Natl. Acad. Sci. USA 2011 108 4129 4134 10.1073/pnas.1014769108 21325052
190. Jung J.E. Lee H. Cho I. Chung D.H. Yoon S. Yang Y.M. Lee J.W. Choi S. Park J. Ye S. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells FASEB J. 2005 19 1296 1298 10.1096/fj.04-3099fje 15919761
191. Yan S. Zhou C. Zhang W. Zhang G. Zhao X. Yang S. Wang Y. Lu N. Zhu H. Xu N. β-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma Cancer Lett. 2008 271 85 97 10.1016/j.canlet.2008.05.035 18602747
192. Sinibaldi D. Wharton W. Turkson J. Bowman T. Pledger W.J. Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling Oncogene 2000 19 5419 5427 10.1038/sj.onc.1203947 11114718
193. Dekanty A. Lavista-Llanos S. Irisarri M. Oldham S. Wappner P. The insulin-PI3K/TOR pathway induces a HIF-dependent transcriptional response in Drosophila by promoting nuclear localization of HIF-α/Sima J. Cell Sci. 2005 118 5431 5441 10.1242/jcs.02648 16278294
194. Milovanova T.N. Bhopale V.M. Sorokina E.M. Moore J.S. Hunt T.K. Hauer-Jensen M. Velazquez O.C. Thom S.R. Lactate Stimulates Vasculogenic Stem Cells via the Thioredoxin System and Engages an Autocrine Activation Loop Involving Hypoxia-Inducible Factor 1 Mol. Cell. Biol. 2008 28 6248 6261 10.1128/MCB.00795-08 18710947
195. Shaw R.J. Glucose metabolism and cancer Curr. Opin. Cell Biol. 2006 18 598 608 10.1016/j.ceb.2006.10.005 17046224
196. Brugarolas J.B. Vazquez F. Reddy A. Sellers W.R. Kaelin W.G. TSC2 Regulates VEGF through MTOR-Dependent and -Independent Pathways Cancer Cell 2003 4 147 158 10.1016/S1535-6108(03)00187-9 12957289
197. Düvel K. Yecies J.L. Menon S. Raman P. Lipovsky A.I. Souza A.L. Triantafellow E. Ma Q. Gorski R. Cleaver S. Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1 Mol. Cell 2010 39 171 183 10.1016/j.molcel.2010.06.022 20670887
198. Land S.C. Tee A.R. Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif J. Biol. Chem. 2007 282 20534 20543 10.1074/jbc.M611782200 17502379
199. Toschi A. Lee E. Gadir N. Ohh M. Foster D.A. Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2 J. Biol. Chem. 2008 283 34495 34499 10.1074/jbc.C800170200 18945681
200. Xu Q. Briggs J. Park S. Niu G. Kortylewski M. Zhang S. Gritsko T. Turkson J. Kay H. Semenza G.L. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways Oncogene 2005 24 5552 5560 10.1038/sj.onc.1208719 16007214
201. Dibble C.C. Cantley L.C. Regulation of mTORC1 by PI3K signaling Trends Cell Biol. 2015 25 545 555 10.1016/j.tcb.2015.06.002 26159692
202. Gan X. Wang J. Su B. Wu D. Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate J. Biol. Chem. 2011 286 10998 11002 10.1074/jbc.M110.195016 21310961
203. Kaur B. Tan C. Brat D.J. Van Meir E.G. Genetic and hypoxic regulation of angiogenesis in gliomas J. Neuro-Oncology 2004 70 229 243 10.1007/s11060-004-2752-5 15674480
204. Ohgaki H. Dessen P. Jourde B. Horstmann S. Nishikawa T. Di Patre P.-L. Burkhard C. Schüler D. Probst-Hensch N.M. Maiorka P.C. Genetic Pathways to Glioblastoma Cancer Res. 2004 64 6892 6899 10.1158/0008-5472.CAN-04-1337 15466178
205. Parliament M.B. Allalunis-Turner M.J. Franko A.J. Olive P.L. Mandyam R. Santos C. Wolokoff B. Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours Br. J. Cancer 2000 82 635 641 10.1054/bjoc.1999.0975 10682677
206. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Oncogene 2009 29 625 634 10.1038/onc.2009.441 19946328
207. Zagzag D. Zhong H. Scalzitti J.M. Laughner E. Simons J.W. Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression Cancer 2000 88 2606 2618 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W 10861440
208. Semenza G.L. Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 2003 3 721 732 10.1038/nrc1187 13130303
209. Brahimi-Horn M.C. Chiche J. Pouysségur J. Hypoxia and cancer J. Mol. Med. 2007 85 1301 1307 10.1007/s00109-007-0281-3 18026916
210. Unruh A. Ressel A. Mohamed H.G. Johnson R.S. Nadrowitz R. Richter E. Katschinski D.M. Wenger R.H. The hypoxia-inducible factor-1α is a negative factor for tumor therapy Oncogene 2003 22 3213 3220 10.1038/sj.onc.1206385 12761491
211. Valvona C.J. Fillmore H.L. Nunn P.B. Pilkington G.J. The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor Brain Pathol. 2015 26 3 17 10.1111/bpa.12299 26269128
212. Gohil K. Brooks G.A. Exercise tames the wild side of the Myc network: A hypothesis Am. J. Physiol. Metab. 2012 303 E18 E30 10.1152/ajpendo.00027.2012
213. Giatromanolaki A. Sivridis E. Gatter K.C. Turley H. Harris A.L. Koukourakis M.I. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis Gynecol. Oncol. 2006 103 912 918 10.1016/j.ygyno.2006.05.043 16837029
214. Kolev Y. Uetake H. Takagi Y. Sugihara K. Lactate Dehydrogenase-5 (LDH-5) Expression in Human Gastric Cancer: Association with Hypoxia-Inducible Factor (HIF-1α) Pathway, Angiogenic Factors Production and Poor Prognosis Ann. Surg. Oncol. 2008 15 2336 2344 10.1245/s10434-008-9955-5 18521687
215. Koukourakis I.M. Giatromanolaki A. Sivridis E. Bougioukas G. Didilis V. Gatter K.C. Harris A.L. for the ‘Tumour and Angiogenesis Research Group’ Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis Br. J. Cancer 2003 89 877 885 10.1038/sj.bjc.6601205 12942121
216. Koukourakis M.I. Giatromanolaki A. Sivridis E. Gatter K.C. Trarbach T. Folprecht G. Shi M.M. Lebwohl D. Jalava T. Laurent D. Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy Clin. Cancer Res. 2011 17 4892 4900 10.1158/1078-0432.CCR-10-2918 21632858
217. Kim J.-W. Dang C.V. Cancer’s Molecular Sweet Tooth and the Warburg Effect: Figure 1 Cancer Res. 2006 66 8927 8930 10.1158/0008-5472.CAN-06-1501 16982728
218. Firth J.D. Ebert B.L. Ratcliffe P.J. Hypoxic Regulation of Lactate Dehydrogenase A. Interaction between Hypoxia-Inducible Factor 1 and CAMP Response Elements J. Biol. Chem. 1995 270 21021 21027 10.1074/jbc.270.36.21021 7673128
219. Lewis B.C. Shim H. Li Q. Wu C.S. Lee A.L. Maity A. Dang C.V. Identification of putative c-Myc-responsive genes: Characterization of RCL, a novel growth-related gene Mol. Cell. Biol. 1997 17 4967 4978 10.1128/MCB.17.9.4967 9271375
220. Semenza G.L. Jiang B.-H. Leung S.W. Passantino R. Concordet J.-P. Maire P. Giallongo A. Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1 J. Biol. Chem. 1996 271 32529 32537 10.1074/jbc.271.51.32529 8955077
221. Shim H. Dolde C. Lewis B.C. Wu C.-S. Dang G. Jungmann R.A. Dalla-Favera R. Dang C.V. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth Proc. Natl. Acad. Sci. USA 1997 94 6658 6663 10.1073/pnas.94.13.6658 9192621
222. Lu R. Jiang M. Chen Z. Xu X. Hu H. Zhao X. Gao X. Guo L. Lactate Dehydrogenase 5 Expression in Non-Hodgkin Lymphoma Is Associated with the Induced Hypoxia Regulated Protein and Poor Prognosis PLoS ONE 2013 8 e74853 10.1371/journal.pone.0074853 24086384
223. Dhup S. Dadhich R.K. Porporato P.E. Sonveaux P. Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth, Angiogenesis and Metastasis Curr. Pharm. Des. 2012 18 1319 1330 10.2174/138161212799504902 22360558
224. Polet F. Feron O. Endothelial cell metabolism and tumour angiogenesis: Glucose and glutamine as essential fuels and lactate as the driving force J. Intern. Med. 2013 273 156 165 10.1111/joim.12016 23216817
225. San-Millán I. Brooks G.A. Reexamining cancer metabolism: Lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect Carcinogenesis 2016 38 119 133 10.1093/carcin/bgw127
226. Lu H. Dalgard C.L. Mohyeldin A. McFate T. Tait A.S. Verma A. Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1 J. Biol. Chem. 2005 280 41928 41939 10.1074/jbc.M508718200 16223732
227. Sonveaux P. Copetti T. De Saedeleer C.J. Végran F. Verrax J. Kennedy K.M. Moon E.J. Dhup S. Danhier P. Frérart F. Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis PLoS ONE 2012 7 e33418 10.1371/journal.pone.0033418 22428047
228. Kerbel R.S. Tumor Angiogenesis N. Engl. J. Med. 2008 358 2039 2049 10.1056/NEJMra0706596 18463380
229. Heiden M.G.V. Cantley L.C. Thompson C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation Science 2009 324 1029 1033 10.1126/science.1160809 19460998
230. Beckert S. Farrahi F. Aslam R.S. Scheuenstuhl H. Königsrainer A. Hussain M.Z. Hunt T.K. Lactate stimulates endothelial cell migration Wound Repair Regen. 2006 14 321 324 10.1111/j.1743-6109.2006.00127.x 16808811
231. Fukumura D. Xu L. Chen Y. Gohongi T. Seed B. Jain R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo Cancer Res. 2001 61 6020 6024 11507045
232. Hirschhaeuser F. Sattler U.G. Mueller-Klieser W. Lactate: A Metabolic Key Player in Cancer: Figure 1 Cancer Res. 2011 71 6921 6925 10.1158/0008-5472.CAN-11-1457 22084445
233. Shi Q. Le X. Wang B. Abbruzzese J.L. Xiong Q. He Y. Xie K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells Oncogene 2001 20 3751 3756 10.1038/sj.onc.1204500 11439338
234. Xu L. Fukumura D. Jain R.K. Acidic Extracellular pH Induces Vascular Endothelial Growth Factor (VEGF) in Human Glioblastoma Cells via ERK1/2 MAPK Signaling Pathway J. Biol. Chem. 2002 277 11368 11374 10.1074/jbc.M108347200 11741977
235. Xu L. Fidler I.J. Acidic PH-Induced Elevation in Interleukin 8 Expression by Human Ovarian Carcinoma Cells Cancer Res. 2000 60 4610 4616 10969814
236. Haaga J.R. Haaga R. Acidic lactate sequentially induced lymphogenesis, phlebogenesis, and arteriogenesis (ALPHA) hypothesis: Lactate-triggered glycolytic vasculogenesis that occurs in normoxia or hypoxia and complements the traditional concept of hypoxia-based vasculogenesis Surgery 2013 154 632 637 10.1016/j.surg.2013.03.007 23859305
237. Trabold O. Wagner S. Wicke C. Bs H.S. Hussain M.Z. Rosen N. Bs A.S. Becker H.D. Hunt T.K. Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing Wound Repair Regen. 2003 11 504 509 10.1046/j.1524-475X.2003.11621.x 14617293
238. Ohgaki H. Kleihues P. The Definition of Primary and Secondary Glioblastoma Clin. Cancer Res. 2013 19 764 772 10.1158/1078-0432.CCR-12-3002 23209033

